TARX (Tarsier Pharma) Research & Development: $2.01 Mil (TTM As of Dec. 2025)


What is Tarsier Pharma Research & Development?

Tarsier Pharma TARX Research & Development is $2.01 Mil as of Dec. 2025.

Research & Development is the aggregate amount of research and development expenses during the year. Tarsier Pharma's Research & Development for the six months ended in Dec. 2025 was $0.98 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $2.01 Mil.

Tarsier Pharma  (NYSE:TARX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Tarsier Pharma Research & Development Related Terms

Tarsier Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma Research & Development Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
3.30 2.03 2.01

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development 0.00 1.05 0.98 1.03 0.98

Tarsier Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $2.01 Mil mean?
Tarsier Pharma (TARX) has a Research & Development of $2.01 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Tarsier Pharma and its competitors.
Is Tarsier Pharma's Research & Development too high?
Tarsier Pharma's current Research & Development is $2.01 Mil.
How does Tarsier Pharma's Research & Development compare to ?
Tarsier Pharma's Research & Development of $2.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Tarsier Pharma and its competitors. Tarsier Pharma's current Research & Development is $2.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current Research & Development of $2.01 Mil. The current Research & Development is $2.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current Research & Development is $2.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.